Percutaneous Coronary Intervention

Long-term risk for coronary revascularization, MI and death persisted up to 5 years after premature discontinuation of dual antiplatelet therapy among patients who underwent PCI, researchers reported.

A protocol involving early use of invasive hemodynamics and mechanical circulatory support conferred a survival benefit in patients with acute MI and cardiogenic shock, a speaker reported.

Colchicine before PCI in patients with acute STEMI to reduce no-reflow phenomenon and improve CV outcomes.

SES with biodegradable polymer (Orsiro, Biotronik) vs. EES with durable polymer (Xience Xpedition/Alpine, Abbott Vascular) for PCI in patients with STEMI.

Patients with STEMI and COVID-19 were less likely to undergo primary PCI and were more likely to experience adverse outcomes compared with those who presented with STEMI before the pandemic, researchers reported.

Among patients with spontaneous coronary artery dissection, or SCAD, medical therapy was comparable to invasive therapy in long-term risk for death, recurrence and repeat revascularization, researchers reported.

Among patients with acute MI, a preloaded dose of colchicine before PCI did not prevent no-reflow phenomenon or improve clinical outcomes, according to results of the PodCAST-PCI trial.

Prasugrel and ticagrelor had similar safety and efficacy among patients with MI receiving PCI, according to results published in Heart.

A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent at 2 years, researchers reported.

The odds of readmission for acute MI or major bleeding after PCI were greater among patients with cancer compared with those with no cancer, with the likelihood varying by cancer type and presence of metastasis, researchers reported.